Table 2 Association of EFGR expression with clinicopathologic features of triple negative breast cancer using different EGFR score cutoffs
| Â | n(%) | Â | P-Value | |||||
|---|---|---|---|---|---|---|---|---|
<50 (n=139) | 50-100 (n=5) | 101-150 (n=1) | 151-200 (n=1) | >200(n=4) | Total (n=150) | |||
Age Group | ≤30 years | 5 (3.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (3.3) | 0.207** |
31-50 years | 78 (56.1) | 1 (20) | 1 (100) | 0 (0) | 4 (100) | 84 (56) | ||
>50 years | 56 (40.3) | 4 (80) | 0 (00 | 1 (100) | 0 (0) | 61 (40.7) | ||
Ki67 Index | ≤15% | 17 (12.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (11.3) | 0.298** |
15-24% | 7 (5) | 1 (20) | 0 (0) | 0 (0) | 0 (0) | 8 (5.3) | ||
25-44% | 41 (29.5) | 0 (0) | 0 (0) | 1 (100) | 3 (75) | 45 (30) | ||
>44% | 74 (53.2) | 4 (80) | 1 (100) | 0 (0) | 1 (25) | 80 (53.3) | ||
Tumor Size | T1(≤2 cm) | 26 (18.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 26 (17.3) | 0.805** |
T2(2.1-4 cm) | 73 (52.5) | 2 (40) | 1 (100) | 1 (100) | 2 (50) | 79 (52.7) | ||
T3(>4 cm) | 40 (28.8) | 3 (60) | 0 (0) | 0 (0) | 2 (50) | 45 (30) | ||
Nodal Stage | N0 | 82 (59) | 3 (60) | 0 (0) | 1 (100) | 2 (50) | 88 (58.7) | 0.536** |
N1 | 27 (19.4) | 1 (20) | 0 (0) | 0 (0) | 2 (50) | 30 (20) | ||
N2 | 12 (8.6) | 1 (20) | 0 (0) | 0 (0) | 0 (0) | 13 (8.7) | ||
N3 | 18 (12.9) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 19 (12.7) | ||
Tumor grade | Grade I | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | 0.435** |
Grade II | 17 (12.2) | 2 (40) | 0 (0) | 0 (0) | 0 (0) | 19 (12.7) | ||
Grade III | 121 (87.1) | 3 (60) | 1 (100) | 1 (100) | 4 (100) | 130 (86.7) | ||
Histological subtypes | IDC | 120 (86.3) | 4 (80) | 0 (0) | 0 (0) | 3 (75) | 127 (84.7) | 0.034* |
Papillary | 4 (2.9) | 1 (20) | 0 (0) | 1 (100) | 0 (0) | 6 (4) | ||
Medullary | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | ||
Metaplastic | 12 (8.6) | 0 (0) | 1 (100) | 0 (0) | 1 (25) | 14 (9.3) | ||
Mixed | 2 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1.3) | ||
Lymphovascular Invasion | Present | 33 (23.7) | 1 (20) | 1 (100) | 0 (0) | 1 (25) | 36 (24) | 0.560** |
Absent | 106 (76.3) | 4 (80) | 0 (0) | 1 (100) | 3 (75) | 114 (76) | ||
Triple negative phenotypes | Basal | 14 (10.1) | 2 (40) | 0 (0) | 0 (0) | 0 (0) | 16 (10.7) | 0.318** |
Non Basal | 125 (89.9) | 3 (60) | 1 (100) | 1 (100) | 4 (100) | 134 (89.3) | ||